Stalicla
Genève, Switzerland · Founded 2017 · $17.4M raised
- Headquarters
- Genève
- Founded
- 2017
- Website
- stalicla.com
- Total Funding
- $17.4M
- Last Round
- $17.4M Series CJun 2025
- Rounds
- 2
About
STALICLA, which was founded in May 2017 by CEO Lynn Durham, is attempting to identify subgroups of patients with idiopathic ASD by utilizing a big data approach, and then planning to treat them using combinations of repurposed drugs. Its Drug Development Unit combines expertise in operations, medicine, and clinical development to bring STALICLA's clinical-stage treatment options closer to patients.
Summary
Stalicla is a Biotech company based in Genève, Switzerland, founded in 2017. It has raised $17.4M in total across 2 rounds, most recently a $17.4M Series C round in Jun 2025. Investors include SPRIM Global Investments.
Funding History
Jun 2025
Sign up to see all 2 rounds
Series B through Series C — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
Altos Labs combines academic science and industry development to create medicines that restore ce...
BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Calico researches human aging using advanced technologies and model systems, applying that knowle...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Global biosimulation software and services company accelerating drug development for 2,000+ bioph...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/stalicla"><img src="https://indexed.vc/api/badge/company/stalicla" alt="Stalicla on Indexed.vc" width="260" height="76" /></a>